These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 12532101)

  • 1. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma.
    Corren J; Casale T; Deniz Y; Ashby M
    J Allergy Clin Immunol; 2003 Jan; 111(1):87-90. PubMed ID: 12532101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma.
    Bousquet J; Wenzel S; Holgate S; Lumry W; Freeman P; Fox H
    Chest; 2004 Apr; 125(4):1378-86. PubMed ID: 15078749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab for asthma in adults and children.
    Normansell R; Walker S; Milan SJ; Walters EH; Nair P
    Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD003559. PubMed ID: 24414989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on omalizumab in allergic asthma.
    Bang LM; Plosker GL
    BioDrugs; 2004; 18(6):415-8. PubMed ID: 15571425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab: a review of its use in the management of allergic asthma.
    Bang LM; Plosker GL
    Treat Respir Med; 2004; 3(3):183-99. PubMed ID: 15219177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-IgE for chronic asthma in adults and children.
    Walker S; Monteil M; Phelan K; Lasserson TJ; Walters EH
    Cochrane Database Syst Rev; 2004; (3):CD003559. PubMed ID: 15266491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR.
    Vignola AM; Humbert M; Bousquet J; Boulet LP; Hedgecock S; Blogg M; Fox H; Surrey K
    Allergy; 2004 Jul; 59(7):709-17. PubMed ID: 15180757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Omalizumab, recombinant humanized monoclonal antibody anti-IgE -- new fields of studies on the therapeutic indications].
    Kupryś-Lipińska I; Kuna P
    Pneumonol Alergol Pol; 2009; 77(1):43-51. PubMed ID: 19308909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma.
    Grimaldi-Bensouda L; Zureik M; Aubier M; Humbert M; Levy J; Benichou J; Molimard M; Abenhaim L;
    Chest; 2013 Feb; 143(2):398-405. PubMed ID: 23505637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma.
    Kulus M; Hébert J; Garcia E; Fowler Taylor A; Fernandez Vidaurre C; Blogg M
    Curr Med Res Opin; 2010 Jun; 26(6):1285-93. PubMed ID: 20377320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma.
    Chung KF
    Expert Opin Pharmacother; 2004 Feb; 5(2):439-46. PubMed ID: 14996639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma.
    Busse W; Corren J; Lanier BQ; McAlary M; Fowler-Taylor A; Cioppa GD; van As A; Gupta N
    J Allergy Clin Immunol; 2001 Aug; 108(2):184-90. PubMed ID: 11496232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of long-term omalizumab treatment in patients with severe allergic asthma long-term omalizumab treatment in severe asthma.
    Özgür ES; Özge C; Ïlvan A; Naycı SA
    J Asthma; 2013 Aug; 50(6):687-94. PubMed ID: 23557459
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.